Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT06377527
- Status
- Recruiting
Conditions
- Mesonephric-like Adenocarcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
To develop a database of medical information about patients with MLA in an effort to increase our understanding of the characteristics of MLA, which is the rarest form of endometrial carcinoma.
Key Dates
- Start date
- Jul 10, 2024
- Status verified
- Dec 2025
- Primary completion
- Dec 28, 2035
- Completion
- Dec 28, 2037
Study Design
- Enrollment
- 2,000 participants (estimated)
Arms
- Arm: Mesonephric-like Adenocarcinoma (MLA)Particpants who agree to take part in this research, information such as your demographics (including your name, date of birth, race, etc.), medical history, surgical history, family history, social history, cancer diagnosis, primary treatment, and follow up will be collected. Participants also have the option to agree to the use of your previously collected tumor tissue samples for future research to better understand MLA.
Primary Outcome Measure
Tumor Registry [ Time Frame: Through study completion; an average of 1 year ]
Central Contacts
- Jeffrey How, MD877-632-6789
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| MD Anderson Cancer Center | Houston | Texas | 77030 | Jeffrey How, MD Jeffrey How, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
By research site